Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

h a median PFS of 8.8 months in the bortezomib-relapsed population.  Median overall survival (OS) was 25 months.  Therapy was generally well-tolerated; toxicities, including gastrointestinal side-effects and fatigue, proved manageable.  No treatment-related mortality was seen.  

The investigators concluded that the combination of perifosine and bortezomib is active and well-tolerated in heavily pre-treated MM patients previously treated with bortezomib, and that the survival data in this study is encouraging, even in patients previously exposed to, and refractory to, bortezomib, as well as prior immunomodulatory drugs.

Data from this study was previously presented at the 2009 American Society of Hematology (ASH) conference.

A copy of the article featured in the current online edition of the Journal of Clinical Oncology can be obtained at http://jco.ascopubs.org/content/early/2011/10/04/JCO.2010.33.9788.full.pdf+html

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (NASDAQ: AEZS) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and approved all parts required to build nine ... to manufacture the new PCT-based instrument system.  The ... for shipment by mid-October and that additional Barozyme ... rate of about one per week thereafter.  ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Diagnostics, one of the leading providers of arrhythmia ... technology with cardiac care to provide leading edge ... eCardio with machine-to-machine (M2M) wireless data ... of cardiac patients. eCardio,s monitoring solution on cardiac ...
... and SEATTLE, Oct. 7 VentiRx Pharmaceuticals, Inc., ... novel Toll-Like Receptor 8 (TLR8) candidates for the ... today results from its randomized, placebo controlled clinical ... rhinitis. The results demonstrated that VTX-1463 significantly improved ...
Cached Medicine Technology:AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 2AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... intact cells to treat and cure disease is ... is hindered by the inability of doctors and scientists ... these cells in patients without resorting to invasive procedures, ... 17 in the online journal Magnetic Resonance in ... Diego School of Medicine, University of Pittsburgh and elsewhere ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2
... Ann Converso, RN, to Serve as President, WASHINGTON, ... the death of President Cheryl L. Johnson,RN. Johnson was ... Oct. 19, with a ruptured brain aneurysm and died ... friends., "Cheryl was a guiding force in the ...
... BASEL, Switzerland, Oct. 29 Roche (SWX: ROG.VX; RO.S),a ... it has extended its offer to acquire all of ... VMSI ),to 5:00 p.m., New York City time ... scheduled to expire at 5:00 p.m., New York City ...
... experts will summarize important new research on the ... consequences of acute kidney injury, racial and ethnic ... kidney disease patients, being presented during the American ... Exposition in San Francisco at a policy-centered news ...
... Fund Launch National Campaign to Inspire and ... Educate that Prevention is Possible, BERKELEY, Calif., Oct. ... in their lifetime. Although 50 percent,of women think breast cancer is ... of the disease. LUNA, the makers of whole nutrition bars ...
... ... Provider Earns $1.6 Million in Rebates This Year, Highlights ... Redwood City Project, REDWOOD ... nation,s largest not-for-profit,health plan, will today celebrate significant energy efficiency upgrades,and solar installations ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... announced today that it will present at the,18th ... York City. The,Company,s presentation is scheduled for Monday, ... Hinson, president and chief executive officer, will,review the ...
Cached Medicine News:Health News:UAN Mourns Passing of President Cheryl L. Johnson, RN 2Health News:Roche Extends Tender Offer for Ventana 2Health News:Roche Extends Tender Offer for Ventana 3Health News:Roche Extends Tender Offer for Ventana 4Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:The Healing Power of Green 2Health News:The Healing Power of Green 3Health News:Cardiac Science to Present at the 18th Annual CIBC World Markets Healthcare Conference 2
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Delicate strong curved serrated tips. Serrated handle with dull finish....
Medicine Products: